FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals' Stock Higher for the Week

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the 11 Best Short-Term Stocks to Invest in.

The company’s weekly stock price performance surges following FDA approvals for EMPAVELI, second-quarter 2025 financial results, and capped royalty purchase agreements.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), headquartered in Massachusetts, is a global biopharmaceutical enterprise advancing treatments for diseases through complement system modulation. The company has pioneered first-in-class C3-targeting therapies for conditions such as geographic atrophy, rare kidney disorders, and PNH.

On July 28, 2025, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) received U.S. FDA approval for EMPAVELI for the treatment of patients 12 years and older with C3 glomerulopathy (C3G) and primary immune complex glomerulonephritis (IC-MPGN). With this approval, EMPAVELI becomes the first and only FDA-approved treatment for primary IC-MPGN, adolescent patients with C3G, and post-transplant C3G disease recurrence, thus capturing the unmet demands for the drug.

On July 31, 2025, the company reported its Q2 2025 financial results, showing $178.5 million in total revenues. SYFOVRE U.S. net product revenue reached $150.6 million, with demand growing 6% quarter-over-quarter, maintaining its market leadership in GA.

In the report, the company also highlighted a capped royalty purchase agreement with Sobi, under which it would receive up to $300 million for 90% of ex-U.S. royalties of Aspaveli, including an upfront cash payment of $275 million. With this, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) focuses on pipeline development and commercial expansion without immediate financial pressure.

Following these developments, the stock price went up 27.70% this week, making a turnaround from its 32.78% yearly loss and drawing interest from traders eyeing biotech bounce-backs.

While we acknowledge the potential of APLS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon

Disclosure. None.